SAN DIEGO, Sept. 4 Lpath, Inc.(OTC Bulletin Board: LPTN), the category leader in therapeutic agents againstbioactive lipids, reported positive results in several murine models of humancancer and AMD with Lpathomab(TM), the company's mouse monoclonal antibodyagainst LPA (lysophosphatidic acid). These results confirm the expected potentanti-angiogenic and anti-metastatic actions of Lpathomab. Lpathomab wascreated using Lpath's proprietary ImmuneY2(TM) platform technology.
Based on this positive outcome, Lpath will collaborate with DataMabs ofLondon, England, to humanize Lpathomab to create a lead antibody for pre-clinical development.
LPA is a bioactive lipid long recognized as a significant promoter ofcancer-cell growth and metastasis in a broad range of tumor types, as well asa significant contributor to neuropathic pain.
"Humanizing our Lpathomab antibody is a vital next step in moving theproject into the clinic," said Genevieve Hansen, Ph.D., Lpath's vice presidentof research. "We've had great success in the past working with DataMabs andlook forward to working with them again on our Lpathomab project."
This achievement with Lpathomab comes on the heels of Lpath's success withits Sphingomab(TM) program. Sphingomab is an antibody against anotherbioactive lipid, S1P. Lpath humanized the antibody in 2006 and plans to filean IND in November of this year for the use of ASONEP(TM) (the systemicformulation of humanized Sphingomab) for the treatment of cancer. It alsoplans to file a second IND early next year for the use of iSONEP(TM) (theocular formulation of humanized Sphingomab) for the treatment of AMD. Thecompany plans to submit an IND filing for the use of humanized Lpathomab in2009.
Dr. Roger Sabbadini, the founder and CSO of Lpath, commented, "Theseexciting results provide further validation of lipidomic-based therapeutics asan important new area of drug discovery. Lpath was one of the first companiesto recognize that bioactive-lipid-signaling molecules, like S1P and LPA, couldbe excellent targets for rational drug design. By pursuing these targets anddemonstrating compelling efficacy, we've opened up an entire class oflipidomic-based therapeutics for the treatment of cancer, diabetes,neurodegenerative disorders, immune function, inflammation, pain, mentaldisorders, and cardiovascular disease."
Scientists now believe that there are over 1,000 members of the functionallipidome, each of which is a new potential target for therapeuticintervention.
Lpath, Inc., headquartered in San Diego, California, is the categoryleader in lipidomics-based therapeutics, an emerging field of medical sciencewhereby bioactive signaling lipids are targeted for treating important humandiseases. ASONEP(TM) (the systemic formulation of humanized form ofSphingomab(TM)) is an antibody against S1P that holds promise for thetreatment of cancer and other diseases. A second product candidate, iSONEP(TM)(the ocular formulation of humanized Sphingomab), has demonstrated superiorresults in various preclinical AMD and retinopathy models. Lpath's thirdproduct candidate, Lpathomab(TM), is an antibody against LPA, a key bioactivelipid that has been long recognized as a valid disease target. The company'sunique ability to generate novel antibodies against bioactive lipids is basedon its ImmuneY2(TM) drug-discovery engine, which the company is using to addto its pipeline. For more information, visit http://www.Lpath.com
Except for statements of historical fact, the matters discussed in thispress release are forward looking and reflect numerous assumptions and involvea variety of risks and uncertainties, many of which are beyond our control andmay cause actual results to differ materially from stated expectations. Forexample, there can be no assurance that required clinical trial